<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964910</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-HE-009</org_study_id>
    <nct_id>NCT02964910</nct_id>
  </id_info>
  <brief_title>A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )</brief_title>
  <official_title>An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability .( Aged 30 Years or Over)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Innovax Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiamen Innovax Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV clinical study was designed to evaluate the immunogenicity and safety of
      Hecolin® in the chronic Hepatitis B patients on the clinical stability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase IV clinical study was designed to evaluate the immunogenicity and safety of the
      recombinant Hepatitis E vaccine(Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD.,
      in the chronic Hepatitis B patients on the clinical stability and aged over 30 years of age
      at enrollment. The study volunteers will receive the 3 doses of Hecolin® administered
      intramuscularly according to a 0-1-6 month schedule.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose</measure>
    <time_frame>Month 7</time_frame>
    <description>Measure the number of participants whose anti-HEV antibody seroconverted at month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations of Anti-HEV Antibody at One Month After The Third Dose</measure>
    <time_frame>Month 7</time_frame>
    <description>Measure the level of anti-HEV antibody in serum samples at month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Wu/ml：World Health Organization (WHO) units per ml. The WHO standard was used to calibrate the antibody quantitative reference.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Liver Function Index Before and One Month After the First Dose</measure>
    <time_frame>Day 0-Month 1</time_frame>
    <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Liver Function Index Before and One Month After the Third Dose</measure>
    <time_frame>Month 6-Month 7</time_frame>
    <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Liver Function Index Before The First Dose and One Month After the Third Dose</measure>
    <time_frame>Day0-Month 7</time_frame>
    <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Any Adverse Reactions/Events</measure>
    <time_frame>Day 0-Month 7</time_frame>
    <description>Any adverse reactions/events contains solicited and unsolicited adverse reactions/events during the whole period of observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Solicited Adverse Reactions/Events</measure>
    <time_frame>Day 0-Day 7</time_frame>
    <description>Number of participants who experienced local, system adverse reactions/events within 7 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Solicited Local Adverse Reactions/Events</measure>
    <time_frame>Day 0-Day 7</time_frame>
    <description>Number of participants who experienced solicited local adverse reactions/events within 7 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Solicited System Adverse Reactions/Events</measure>
    <time_frame>Day 0-Day 7</time_frame>
    <description>Number of participants who experienced solicited system adverse reactions/events within 7 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Unsolicited Adverse Reactions/Events</measure>
    <time_frame>Day 0-Month 7</time_frame>
    <description>Number of participants who experienced unsolicited adverse reactions/events during the whole period of observation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Hepatitis E</condition>
  <arm_group>
    <arm_group_label>the chronic Hepatitis B patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the healthy volunteer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Hepatitis E Vaccine (Escherichia Coli)</intervention_name>
    <description>Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
    <arm_group_label>the chronic Hepatitis B patients</arm_group_label>
    <arm_group_label>the healthy volunteer</arm_group_label>
    <other_name>Hecolin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria(all volunteers):

          1. Aged over 30 years old on the day of enrollment

          2. Axillary temperature is below than 37.0 ℃.

          3. No administration of HEV vaccine before the study

          4. Judged as healthy and eligible for vaccination by the investigators through a
             selfreported medical history and some physical examinations.

          5. Able to understand this study information and willing to comply with all study
             requirements.

          6. Willing to participate in this study and sign informed consent form.

          7. Negative serological markers for hepatitis E

        Inclusion Criteria(experiment group):

          1. ALT &lt; 1.5×ULN

          2. No spleen swelling,no cirrhosis and no hepatocellular carcinoma

        Inclusion Criteria(control group):

        1. HBsAg(-)

        Exclusion Criteria:

          1. With clinical evidence of malignant tumor

          2. History of severe cardio-cerebrovascular disease

          3. Administration of hepatotoxicity drugs before or during the study

          4. Pregnancy,breast-feeding or plan to be pregnant in 7 months later

          5. Participated in any other clinical trial during the study period.

          6. Use of any investigational product or non-registered product (drug or vaccine)within
             30 days preceding the first dose of the study vaccine or plan to use during the study
             period.

          7. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy
             for more than 14 days in the 6 months before entry, except local treatment.

          8. Administration of any immunoglobulin or blood products within 3 months preceding the
             first dose of the study vaccine,or plan to use during the study period.

          9. Administration of any inactivated vaccines within 14 days preceding the first dose of
             the study or attenuated live vaccines within 21 days preceding the first dose of the
             study.

         10. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring
             systemic antibiotics or antiviral treatment within 5 days before vaccination.

         11. Immunodeficiency (such as HIV carriers), primary disease of important organs,
             malignant tumor, or any immune disease (such as systemic lupus erythematosus,
             arthritis pauperum, splenectomy or functional asplenia or other disease which might
             affect immune response).

         12. History of allergic disease or history of serious adverse events occurring after
             vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain.

         13. Allergic history to any component of this vaccine.

         14. Asthma that needed emergency treatment, hospitalization, oral or intravenous
             corticosteroid to keep stable in the past two years.

         15. Combining another severe internal medicine disease(such as severe hypertension,
             cardiopathy,diabetes and hyperthyroidism)

         16. Anomal coagulation function or coagulopathy diagnosed by doctor

         17. Epilepsy(not including alcohol epilepsy within 3 years prior to abstinence and simple
             epilepsy that do without curing within 3 years prior to the study )

         18. Anomal psychology or mind affecting the individual's ability to obey the study requie

         19. Other medical, psychological, social or occupational factors that, according to the
             investigators' judgment,might affect the individual's ability to obey the protocol or
             sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiqiang Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rushan Center for Disease Control and Prevention</name>
      <address>
        <city>Weihai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <results_first_submitted>December 12, 2018</results_first_submitted>
  <results_first_submitted_qc>July 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 25, 2019</results_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis E</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02964910/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>the Chronic Hepatitis B Patients</title>
          <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
        </group>
        <group group_id="P2">
          <title>the Healthy Volunteer</title>
          <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>the Chronic Hepatitis B Patients</title>
          <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
        </group>
        <group group_id="B2">
          <title>the Healthy Volunteer</title>
          <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="235"/>
            <count group_id="B2" value="240"/>
            <count group_id="B3" value="475"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="235"/>
                    <count group_id="B2" value="240"/>
                    <count group_id="B3" value="475"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="9.7"/>
                    <measurement group_id="B2" value="53.4" spread="9.5"/>
                    <measurement group_id="B3" value="53.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="235"/>
                    <count group_id="B2" value="240"/>
                    <count group_id="B3" value="475"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose</title>
        <description>Measure the number of participants whose anti-HEV antibody seroconverted at month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.</description>
        <time_frame>Month 7</time_frame>
        <population>Totally 192 CHB participants and 196 healthy participants were involved in per-protocol set, who meet the meet the requirements 1) whole-course inoculation, 2)having the results of anti-HEV antibody test before and after immunization, 3) anti-HEV antibody negative before immunization.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose</title>
          <description>Measure the number of participants whose anti-HEV antibody seroconverted at month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.</description>
          <population>Totally 192 CHB participants and 196 healthy participants were involved in per-protocol set, who meet the meet the requirements 1) whole-course inoculation, 2)having the results of anti-HEV antibody test before and after immunization, 3) anti-HEV antibody negative before immunization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The criteria of the immunogenicity non-inferiority between CHB group and healthy adults group were: the lower limit of 95% CI of the seroconversion rate difference was not less than -10%.</non_inferiority_desc>
            <param_type>the seroconversion rate difference(%)</param_type>
            <param_value>-2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.23</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations of Anti-HEV Antibody at One Month After The Third Dose</title>
        <description>Measure the level of anti-HEV antibody in serum samples at month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Wu/ml：World Health Organization (WHO) units per ml. The WHO standard was used to calibrate the antibody quantitative reference.</description>
        <time_frame>Month 7</time_frame>
        <population>Totally 192 CHB participants and 196 healthy participants were involved in per-protocol set, who meet the meet the requirements 1) whole-course inoculation, 2)having the results of anti-HEV antibody test before and after immunization, 3) anti-HEV antibody negative before immunization.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Anti-HEV Antibody at One Month After The Third Dose</title>
          <description>Measure the level of anti-HEV antibody in serum samples at month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Wu/ml：World Health Organization (WHO) units per ml. The WHO standard was used to calibrate the antibody quantitative reference.</description>
          <population>Totally 192 CHB participants and 196 healthy participants were involved in per-protocol set, who meet the meet the requirements 1) whole-course inoculation, 2)having the results of anti-HEV antibody test before and after immunization, 3) anti-HEV antibody negative before immunization.</population>
          <units>Wu/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.89" lower_limit="9.86" upper_limit="14.35"/>
                    <measurement group_id="O2" value="17.35" lower_limit="15.57" upper_limit="19.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The criteria of the immunogenicity non-inferiority between CHB group and healthy adults group were: the lower limit of 95%CI of the GMC ratio was not lower than 0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changes in Liver Function Index Before and One Month After the First Dose</title>
        <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
        <time_frame>Day 0-Month 1</time_frame>
        <population>All the participants who visited at one month after the first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Liver Function Index Before and One Month After the First Dose</title>
          <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
          <population>All the participants who visited at one month after the first dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TBIL</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changes in Liver Function Index Before and One Month After the Third Dose</title>
        <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
        <time_frame>Month 6-Month 7</time_frame>
        <population>All the participants who visited at one month after the third dose.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Liver Function Index Before and One Month After the Third Dose</title>
          <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
          <population>All the participants who visited at one month after the third dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TBIL</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changes in Liver Function Index Before The First Dose and One Month After the Third Dose</title>
        <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
        <time_frame>Day0-Month 7</time_frame>
        <population>All the participants who visited at one month after the third dose.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Liver Function Index Before The First Dose and One Month After the Third Dose</title>
          <description>ALT, AST and TBIL were detected in both groups to determine the liver function of participants. The grade of ALT, AST and TBIL was determined according to the rules issued by CFDA. The fluctuations were classified into three categories: &quot;no change&quot; indicated no grade change; &quot;processed&quot; indicated a change from normal to abnormal or an increase in grade; and &quot;improved&quot; indicated a change from abnormal to normal or a decrease in grade or the change from abnormal to normal.</description>
          <population>All the participants who visited at one month after the third dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TBIL</title>
              <category_list>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>processed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Any Adverse Reactions/Events</title>
        <description>Any adverse reactions/events contains solicited and unsolicited adverse reactions/events during the whole period of observation.</description>
        <time_frame>Day 0-Month 7</time_frame>
        <population>All the participants who received at least one injection.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Any Adverse Reactions/Events</title>
          <description>Any adverse reactions/events contains solicited and unsolicited adverse reactions/events during the whole period of observation.</description>
          <population>All the participants who received at least one injection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The differences in incidence rate of ADR\AE between the two groups were compared.</non_inferiority_desc>
            <p_value>0.778</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Solicited Adverse Reactions/Events</title>
        <description>Number of participants who experienced local, system adverse reactions/events within 7 days after each vaccination.</description>
        <time_frame>Day 0-Day 7</time_frame>
        <population>All the participants who received at least one injection.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Solicited Adverse Reactions/Events</title>
          <description>Number of participants who experienced local, system adverse reactions/events within 7 days after each vaccination.</description>
          <population>All the participants who received at least one injection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The differences in incidence rate of ADR\AE between the two groups were compared.</non_inferiority_desc>
            <p_value>0.728</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Solicited Local Adverse Reactions/Events</title>
        <description>Number of participants who experienced solicited local adverse reactions/events within 7 days after each vaccination.</description>
        <time_frame>Day 0-Day 7</time_frame>
        <population>All the participants who received at least one injection.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Solicited Local Adverse Reactions/Events</title>
          <description>Number of participants who experienced solicited local adverse reactions/events within 7 days after each vaccination.</description>
          <population>All the participants who received at least one injection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The differences in incidence rate of ADR\AE between the two groups were compared.</non_inferiority_desc>
            <p_value>0.949</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Solicited System Adverse Reactions/Events</title>
        <description>Number of participants who experienced solicited system adverse reactions/events within 7 days after each vaccination.</description>
        <time_frame>Day 0-Day 7</time_frame>
        <population>All the participants who received at least one injection.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Solicited System Adverse Reactions/Events</title>
          <description>Number of participants who experienced solicited system adverse reactions/events within 7 days after each vaccination.</description>
          <population>All the participants who received at least one injection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The differences in incidence rate of ADR\AE between the two groups were compared.</non_inferiority_desc>
            <p_value>0.614</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Unsolicited Adverse Reactions/Events</title>
        <description>Number of participants who experienced unsolicited adverse reactions/events during the whole period of observation.</description>
        <time_frame>Day 0-Month 7</time_frame>
        <population>All the participants who received at least one injection.</population>
        <group_list>
          <group group_id="O1">
            <title>the Chronic Hepatitis B Patients</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
          <group group_id="O2">
            <title>the Healthy Volunteer</title>
            <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Unsolicited Adverse Reactions/Events</title>
          <description>Number of participants who experienced unsolicited adverse reactions/events during the whole period of observation.</description>
          <population>All the participants who received at least one injection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The differences in incidence rate of ADR\AE between the two groups were compared.</non_inferiority_desc>
            <p_value>0.956</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-7 months</time_frame>
      <desc>The definitions of &quot;All-Cause Mortality&quot;,&quot;Serious Adverse Events&quot; and &quot;Adverse Events&quot; are consistent with the clinicaltrials.gov Definitions.
One death was due to myocardial infarction.</desc>
      <group_list>
        <group group_id="E1">
          <title>the Chronic Hepatitis B Patients</title>
          <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
        </group>
        <group group_id="E2">
          <title>the Healthy Volunteer</title>
          <description>Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
Recombinant Hepatitis E Vaccine (Escherichia Coli): Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Other</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0">Hypertension</sub_title>
                <description>Grade 3: SBP≥180mmHg and\or DBP≥110mmHg</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 19.0">subacute thyroiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>VertebrobasilarArtery Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention</name_or_title>
      <organization>Shandong Center for Disease Control and Prevention, Jinan, China</organization>
      <phone>0531-82679606</phone>
      <email>aqxuepi@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

